Living Cell Technologies’ Russian Phase I/IIa Diabetes Trial Meets End Points
The data analysis has confirmed that the trial has met its end points of demonstrating safety and tolerability. In addition, the treatment has shown proof of principle of
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.
The agreement provides CancerGuide with exclusive commercial rights to a portfolio of well-published and rigorously-validated molecular signatures that predict response for targeted therapeutics as well as collaborative access
Cantox and Ashuren are global scientific research and regulatory consulting organisations providing solutions for clients in food and nutrition, agriculture, biotechnology, consumer products, chemicals, pharmaceuticals and healthcare. The
The System 1E is indicated for liquid chemical sterilization of cleaned, immersible, and reusable critical and semi-critical heat sensitive medical devices in healthcare facilities. Steris continues dialogue with
Integrium works with specialty, development-stage, mid-size, and large biopharmaceutical and medical device companies, providing a complete range of clinical trial management services for Phase I through Phase IV